



REGULATED INFORMATION • REGULATED INFORMATION • REGULATED INFORMATION

ANNUAL REPORT ON THE LIQUIDITY CONTRACT

Paris and Boston, January 12, 2017 - Neovacs (Alternext Paris : ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.

The liquidity account had the following holdings as of December 31, 2016:

- 394 422 shares
- 134 790,14€

For the prior (June 30, 2016), the corresponding figures were:

- 499,961 shares
- €44.083,73

About Neovacs

Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α -Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

NEOVACS – Corporate Communication & Investor Relations

Charlène Masson - cmasson@neovacs.com

LifeSci Advisors– Communication financière et Relations Investisseurs

Chris Maggos- chris@lifesciadvisors.com